CaliciX™ is an oral antiviral therapy designed to suppress feline calicivirus (FCV) and help reduce viral burden in affected cats. It is commonly used in FCV-associated conditions such as chronic oral inflammation, stomatitis, and ulcerative lesions, where ongoing viral replication contributes to persistent pain, tissue damage, and poor treatment response.

CaliciX™ contains EIDD-1931, a targeted antiviral compound that inhibits viral replication at its source. Rather than merely managing surface symptoms, CaliciX™ is designed to address the underlying viral driver of calicivirus-associated oral disease, supporting more durable clinical improvement.

CaliciX™ is commonly considered for mild to moderate feline calicivirus (FCV)–associated disease, particularly in cases of persistent or recurrent oral involvement. Final treatment decisions should always be made by a licensed veterinarian, based on the cat’s clinical presentation and overall health status.

Yes. Under veterinary guidance, CaliciX™ may be used to support cats diagnosed with feline chronic gingivostomatitis (FCGS) and other calicivirus-associated oral inflammatory conditions, where viral activity is believed to contribute to ongoing disease and treatment resistance.

No. CaliciX™ is intended to be part of a veterinarian-guided treatment plan and does not replace dental care, pain management, or other supportive therapies when required.

No. CaliciX™ is not an antibiotic. Antibiotics do not treat viral infections like calicivirus, although they may be prescribed separately by veterinarians to manage secondary bacterial infections.

CaliciX™ is administered orally, providing a simple, non-invasive, and pain-free approach to managing feline calicivirus (FCV)–associated disease.

Yes. Use in kittens should be carefully evaluated by a licensed veterinarian, with consideration given to the kitten’s age, body weight, and overall health status before initiation of therapy.

No. CaliciX™ does not contain molnupiravir (EIDD-2801). It contains EIDD-1931, the active antiviral form related to molnupiravir, and is formulated specifically for veterinary use in cats, with feline-appropriate dosing and clinical intent.

CaliciX™ may be considered when a cat shows: Persistent mouth ulcers Chronic oral inflammation Recurrent calicivirus symptoms Poor response to supportive care alone

Yes. Cats with chronic or recurrent feline calicivirus (FCV)–associated disease may benefit from longer-term management strategies. Treatment duration should always be determined by a licensed veterinarian, based on the cat’s clinical response and ongoing assessment.

Yes. CaliciX™ is intended for veterinary-guided use only. Treatment decisions should always involve a licensed veterinarian.